Objectives-To determine whether fetuses with an isolated aberrant course of the right subclavian artery (ARSA) have increased risk for chromosomal abnormalities, including trisomy 21 or 22q11 deletion.
A n aberrant right subclavian artery (ARSA) is the most common branching abnormality of the aortic arch, and is a variant in 1 to 1.5% of the healthy population. [1] [2] [3] In contrast to the normal aortic arch branching pattern, in which the right subclavian artery branches off the brachiocephalic trunk, an ARSA arises as a fourth aortic arch vessel and passes behind the trachea and esophagus and courses to the right arm. 3, 4 In general, an ARSA is a benign finding, although it is one cause of dysphagia 5 or dyspnea 6 in the pediatric population as a result of compression of the trachea or esophagus by the aberrant vessel.
In the fetus, an ARSA can easily be identified at the level of the transverse 3-vessel tracheal view arising at the junction of the aortic arch and ductal arches of the heart by adjusting color velocities downward to the 15 to 30 cm/s range, and ensuring that the expected course of the aberrant vessel behind the trachea is toward or away from the transducer 7 ( Figure 1A and B, and Video 1). Using pulsed Doppler, an arterial signal should be sought, which can avoid confusing an ARSA ( Figure 1B ) with the normally seen azygous vein that courses toward the SVC 7 and demonstrates a venous waveform ( Figure  1C ). The course of the ARSA can also be followed toward the right shoulder in real time, which makes it easy to determine whether the vessel of interest is an ARSA (see Video 1) or the azygous vein (see Video 2) .
Over the last 10 years, ARSA has emerged as a marker of trisomy 21, increasing the fetal risk for trisomy 21 with a likelihood ratio of 21.5. 8 Most fetuses with trisomy 21, however, have additional anatomic abnormalities 7, [9] [10] [11] [12] in addition to the ARSA. An ARSA has also been reported in fetuses with other, less common, genetic anomalies, 9,13-15 including 22q11.2 deletion. 14, 16, 17 However, neither the incidence of ARSA in fetuses with these genetic anomalies, nor the incidence of these genetic anomalies in fetuses with ARSA, has been established. 14, 15 The purpose of this study was to determine whether in fetuses with ARSA, in the absence of other ultrasound findings, the likelihood of trisomy 21 or other genetic anomalies (in particular 22q11.2 deletion) is increased, and whether cell-free fetal DNA (cfDNA) screening or invasive testing should be considered.
Materials and Methods
After internal review board approval, we performed a retrospective chart review of all fetuses diagnosed antenatally with ARSA between 2009 and 2014 in the fetal ultrasound units of Saint Peter's University Hospital, New Brunswick, New Jersey, and the University Hospitals Leuven, Leuven, Belgium. Cases were ascertained from institutional databases, and hospital charts were reviewed. We collected data from first trimester and targeted fetal anatomy ultrasound scans, fetal echocardiograms, genetic studies (preimplantation genetic screening, karyotype, microarrays, cfDNA, and FISH) for 22q11.2 deletion as available, and reviewed all neonatal and pediatric cardiac records through 1 year of age. Fetuses were excluded if they delivered outside our hospitals without karyotype or cfDNA screening and neonatal records were not available, or if the patient declined all forms of genetic screening or testing and autopsy.
As per institutional protocols, when an ARSA was identified, a targeted ultrasound examination was performed, searching for aneuploidy markers or genetic syndromes. An advanced fetal cardiac ultrasound was performed either at the time of diagnosis or within 1 to 2 weeks. Women were counseled about the risk for aneuploidy and offered amniocentesis at the time of diagnosis if prior chromosome testing with chorionic villous testing (CVS) or amniocentesis had not been previously performed.
For this study, we also retrieved the patient's best risk calculation for trisomy 21, using the prenatal screening technique with the highest detection rate available for the patient (maternal age, first trimester nuchal translucency, and biochemical testing [first screen] in the first trimester, or nuchal translucency and biochemistry in both the first and second trimesters [sequential screen]). We used sequential screen, first screen and maternal age, in that order, as the best a priori risk. Using the patient's best a priori risk, the patient's final risk for trisomy 21 was adjusted by the ultrasound findings using a risk assessment calculator. 8 
Results
Seventy-nine fetuses with ARSA were identified during routine or targeted ultrasound examinations at an average gestational age of 20.3 6 3.8 weeks. The mean maternal age was 32 (range 21-42) years. Two fetuses were excluded as they delivered outside our institutions, without karyotype, cfDNA, or neonatal records available.
An additional fetus that had multiple findings consistent with trisomy 21 was excluded, as the patient declined all genetic screening, testing, and autopsy after intrauterine fetal death at 26 weeks of gestation.
Of the 76 fetuses with evaluable data, 48 (63.2%) had chromosome screening or testing. One patient had preimplantation genetic screening for aneuploidy during the in vitro fertilization procedures and declined further testing, 5 had cfDNA as the only test, 3 had CVS, 38 had amniocentesis, and one had a neonatal microarray. Thirty-eight fetuses (50%) had 22q11.2 deletion evaluated either by quantitative fluorescent-polymerase chain reaction (QF-PCR) or microarray. The remainder of the fetuses were discharged from the nursery without a suspicion of a chromosome abnormality. No fetus or neonate was found to have evidence of 22q11.2 deletion by QF-PCR, microarray, or neonatal examination.
Seven (9.2%) fetuses were diagnosed with trisomy 21, six with full trisomy 21, and one with a translocation (Table 1 ). All but one fetus with trisomy 21 had abnormal screening results (maternal age, first screen, or sequential screen) and fulfilled criteria for invasive testing, even without the detection of the ARSA. One fetus (Case 3, Table 1 ) had a low screening risk and would not have been diagnosed had it not been for an amniocentesis triggered by the combination of ARSA with an echogenic intracardiac focus in a fetus that was 7 days smaller than expected in the second trimester after accurate dating by first trimester ultrasound. Four fetuses (5%) had abnormal microarray results other than trisomy 21 or 22q11.2 deletion, three were identified in the antenatal period, and one in the neonatal period ( Table 2 ). All had additional structural anomalies identified on ultrasound. However, one fetus (Case 1, Table 2 ) only had an echogenic intracardiac focus and would not have undergone invasive testing if the ARSA had not been identified.
The ARSA was apparently isolated in 43 fetuses, none of whom had or were suspected to have trisomy 21 or 22q11.2 deletion. Of these fetuses, 17 (39.5%) underwent invasive genetic testing, and 6 (14.0%) had cfDNA.
Among all fetuses with structural anomalies, the most common associated findings were soft markers for trisomy 21 (n 5 25), cardiac malformations (n 5 11; ventricular septal defect (VSD) 6, complex cardiac disease 3, atrioventricular septal 1, abnormal cardiac axis 1), and a single umbilical artery (n 5 5) (Tables 1 and 2 ). Additional anomalies not associated with aneuploidy were found in 22 fetuses (28.9%), including 9 (11.8%) with a single anomaly and 13 (17.1%) with multiple abnormalities (Table 3) . When additional markers were seen, 23 of 33 (66.7%) fetuses had karyotyping.
Nine women chose to interrupt the pregnancy as a result of trisomy 21 (5), de novo deletion (1), retinoic acid embryopathy (1), VATER (1), and arachnoid cyst (1) . Neonatal death occurred in two cases: one as a result of extreme prematurity (24 weeks of gestation), and one because of hypoplastic left heart syndrome.
Excluding cases that did not progress to term, the gestational age at birth was 37.5 6 3.3 weeks and the birth weight was 2947 6 931 g. Two neonates were unexpectedly admitted to the neonatal ICU for poor respiratory effort and feeding difficulties for 5 days, unrelated to the ARSA. They were discharged without an additional diagnosis. Three others were admitted for prematurity. There was one neonatal readmission for sepsis evaluation at 9 months of age, but none for suspected chromosome abnormalities including 22q11.2 deletion. No neonate had respiratory issues in the newborn period, and none were readmitted for feeding or respiratory issues up to 1 year of age. 
Discussion
This study shows that an apparently isolated ARSA is not associated with genetic anomalies. This is consistent with the conclusion of a recent large study 12 and metaanalysis, 13 and confirms that an isolated ARSA is a likely a normal variant.
In association with other malformations, however, the risk of chromosomal anomalies in a fetus with ARSA is elevated. Indeed, 12 of the 27 fetuses (44%) with ARSA and other (minor) structural anomalies in our series had genetic anomalies, two-thirds of which were trisomy 21. Our data therefore confirm the findings of others that all cases of Down syndrome with ARSA had associated ultrasound findings. 7, [18] [19] [20] Recently, noninvasive genetic screening using cfDNA has been introduced into clinical practice. This test has excellent sensitivity for trisomy 21, and good sensitivities for trisomies 18 and 13, 21 but does not screen for other aneuploidies. From the present data, it seems inappropriate to recommend cfDNA testing as a second line investigation in fetuses diagnosed with ARSA and other malformations or soft markers, as about a third of genetic anomalies will be missed. Similarly, QF-PCR for 22q11.2 deletion, which was used before the widespread availability of microarray, and regular karyotyping clearly appear to be inferior to microarray in this population.
Strikingly, 2 of the 12 fetuses with genetic anomalies in our study would likely not have been identified, had it not been for the presence of an ARSA (Case 3, Table 1 ; Case 1, Table 2 ). This points to the potential clinical relevance of incorporating the ARSA in routine screening, and the necessity of an excellent, structured anatomic survey that looks for additional soft markers and an echocardiogram in all fetuses with ARSA. From our study, an echogenic intracardiac focus, which is typically considered a normal variant, 22 a hypoplastic nasal bone or a VSD, may be of relevance in the fetus with ARSA.
Finally, although 22q11.2 deletion has been reported in a fetus with ARSA, 14 we did not identify a single case with 22q11.2 deletion in our series of 76 cases, suggesting that its incidence in this population is low.
Our study certainly has some limitations. As this is a retrospective study in two referral centers, we were unable to calculate the incidence of ARSA in the general population. Moreover, some fetuses with isolated ARSA may not have been referred to us, as they either went undiagnosed on routine screening in other hospitals or were considered irrelevant. It is unlikely, however, that we missed ARSAs in fetuses with anomalies, as anomalous fetuses are carefully screened in our centers and ARSA is typically looked for on targeted ultrasound examinations and fetal echocardiography in both of our units.
In summary, ARSA can easily be identified on a screening ultrasound examination and is a normal variant in most fetuses. Apparently, isolated ARSA is not associated with trisomy 21 or 22q11.2 deletion; however, the presence of an ARSA mandates advanced ultrasound. If other soft markers or major anomalies are identified, cfDNA is not sufficient for screening. Invasive genetic testing by microarray is recommended.
